Sanuwave Health reports preliminary Q1 2026 revenue of $9.6-$9.7M, up 3-4% YoY

SANUWAVE Health, Inc.

2026-Q1 EPS reported -$0.17 revenue$9,619,000

Revenue expected $9.6M-$9.7M, 3-4% increase vs Q1 2025, within prior guidance.
CEO notes several large deals slid out of Q1, impacting the lower end of guidance.
Wound care market facing reimbursement changes for skin substitutes, causing pause.
High interest at SAWC conference; CEO says they are leaning in, not pulling back.
Preliminary results subject to adjustment after completion of quarter-end close.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SANUWAVE Health, Inc. reported first quarter ended March 31, 2026 results: revenue $9.6 million to $9.7 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $9.6 million to $9.7 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year

View on SEC.gov

1346 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-025553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.